Under construction – not a live service
Sign in
Taking peopleNo phase

AI Health Coach and Monitoring Device for Heart, Kidney and Diabetes Patients

Tests an AI health coach and device in adults with heart, kidney or diabetes disease.

Plain-language title generated from the registry record
Registry title: Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment

Key facts

Where
Stockholm, SwedenSee the site

Where in Sweden

  • Karolinska University HospitalStockholm, SwedenNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Aventyn, Inc.
Trial code
NCT07403669
Record updated
12 February 2026
Original description
The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and vital sign monitoring device in reducing CKM disease burden using an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment.Read full original descriptionShow less

Cardiovascular Kidney and Metaboolic (CKM) Health Assessment and Patient Empowerment in chROnic Disease Using a Health Coach INtervention ModEl: A Randomized Clinical Trial

The primary objective of CHAPERONE solution is to evaluate the efficacy of engaging, assessing, and enabling long term treatment strategy with Health Artificial Intelligence (AI) Chatbot, Copilot, Large Language Model (LLM) and vital sign monitoring device in reducing CKM disease burden using an algorithm obtained from biomarkers and diagnostics utilizing remote sensor driven technology tools, care coordination and patient empowerment.

Inclusion: Men and women over 18 years of age are included; Eligible subjects must have one of the risk factor/ disease component of CKM:; Diabetes with A1C of 7.5 or higher; or Heart disease with stent placement; or Coronary Artery Bypass Graft (CABG) in the last 12 months; or Chronic Kidney Disease (CKD) stage 2- 4; and, in those with Heart failure, a recent hospitalization within one week of enrollment is required.

Exclusion: Those subjects who are not willing to sign an informed consent.

ClinicalTrials.gov NCT07403669